D. Gargot

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial

Thierry Conroy, Jean-François Bosset, Pierre-Luc Etienne et al. · The Lancet Oncology · 2021 · 1.3K citations

Medicine, Oncology, Surgery +17

Geriatric Factors Predict Chemotherapy Feasibility: Ancillary Results of FFCD 2001-02 Phase III Study in First-Line Chemotherapy for Metastatic Colorectal Cancer in Elderly Patients

Thomas Aparicio, Jean–Louis Jouve, Laurent Teillet et al. · Journal of Clinical Oncology · 2013 · 215 citations · Full text

Medicine, Geriatric Medicine, Oncology +17

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial

Thierry Conroy, Florence Castan, Pierre-Luc Etienne et al. · Annals of Oncology · 2024 · 192 citations · Full text

Medicine, Oncology, Surgery +17

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.

Thierry Conroy, Najib Lamfichekh, Pierre-Luc Etienne et al. · Journal of Clinical Oncology · 2020 · 177 citations

Medicine, Oncology, Surgery +17

Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000–05): an open-label, randomised, phase 3 trial

Michel Ducreux, David Malka, Jean Mendiboure et al. · The Lancet Oncology · 2011 · 155 citations

Medicine, Oncology, Chemotherapy +5